1. Report Introduction 2. Nontuberculous Mycobacterial Infections 2.1. Nontuberculous Mycobacterial Infections Disease Overview 2.2. Nontuberculous Mycobacterial Infections History 2.3. Nontuberculous Mycobacterial Infections Symptoms 2.4. Nontuberculous Mycobacterial Infections Causes 2.5. Nontuberculous Mycobacterial Infections Pathophysiology 2.6. Nontuberculous Mycobacterial Infections Diagnosis 2.6.1. Diagnostic Guidelines 3. Nontuberculous Mycobacterial Infections Current Treatment Patterns 3.1. Treatment Guidelines 4. Nontuberculous Mycobacterial Infections- DelveInsight’s Analytical Perspective 4.1. In-depth Commercial Assessment 4.1.1. Nontuberculous Mycobacterial Infections companies collaborations, Licensing, Acquisition –Deal Value Trends 4.1.1.1. Assessment Summary 4.1.2. Nontuberculous Mycobacterial Infections Collaboration Deals 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis 4.1.2.2. Nontuberculous Mycobacterial Infections Acquisition Analysis 4.2. Clinical Assessment of Pipeline Drugs 4.2.1. Assessment by Phase of Development 4.2.2. Assessment by Product Type (Mono / Combination) 4.2.2.1. Assessment by Stage and Product Type 4.2.3. Assessment by Route of Administration 4.2.3.1. Assessment by Stage and Route of Administration 4.2.4. Assessment by Molecule Type 4.2.4.1. Assessment by Stage and Molecule Type 4.2.5. Assessment by MOA 4.2.5.1. Assessment by Stage and MOA 5. Nontuberculous Mycobacterial Infections Pipeline Therapeutics 5.1. Late Stage Products (Phase-III) 5.1.1. Comparative Analysis 5.2. Mid Stage Products (Phase-II) 5.2.1. Comparative Analysis 5.3. Early Stage Products (Phase-I) 5.3.1. Comparative Analysis 5.4. Pre-clinical and Discovery Stage Products 5.4.1. Comparative Analysis 5.5. Inactive Products 6. Nontuberculous Mycobacterial Infections-Products Analysis 6.1. Product Profiles 6.1.1. Molgradex- Savara Inc 6.1.1.1. Product Description 6.1.1.1.1. Product Overview 6.1.1.1.2. Mechanism of Action 6.1.1.2. Research and Development 6.1.1.2.1. Clinical Studies 6.1.1.2.1.1. Detailed Study Description 6.1.1.2.1.2. Study Results 6.1.1.2.1.3. Clinical Trials: Tabular View 6.1.1.3. Product Development Activities 6.1.1.3.1. Tabulated Product Summary 6.1.1.3.1.1. General Description Table 6.1.2. SPR 720- Vertex Pharmaceuticals 6.1.2.1. Product Description 6.1.2.1.1. Product Overview 6.1.2.1.2. Mechanism of Action 6.1.2.2. Research and Development 6.1.2.2.1. Clinical Studies 6.1.2.2.1.1. Detailed Study Description 6.1.2.2.1.2. Study Results 6.1.2.2.1.3. Clinical Trials: Tabular View 6.1.2.3. Product Development Activities 6.1.2.3.1. Tabulated Product Summary 6.1.2.3.1.1. General Description Table To be continued in the report………………………… 7. Recent Technologies 8. Nontuberculous Mycobacterial Infections Key Companies 8.1. Savara Pharmaceuticals 8.2. Vertex Pharmaceuticals 8.3. Matinas BioPharma 8.4. Beyond Air 8.5. Hsiri Therapeutics 8.6. RedHill Biopharma 9. Nontuberculous Mycobacterial Infections Key Products 9.1. Molgramostim 9.2. SPR 720 9.3. Encochleated amikacin 9.4. Nitric oxide inhalation 9.5. Research programme: mycobacterial disease therapeutics 9.6. Clarithromycin/clofazimine/rifabutin 10. Dormant and Discontinued Products 10.1. Dormant Products 10.1.1. Reasons for being dormant 10.2. Discontinued Products 10.2.1. Reasons for the discontinuation 11. Nontuberculous Mycobacterial Infections- Unmet Needs 12. Nontuberculous Mycobacterial Infections- Future Perspectives 13. Appendix 14. Report Methodology 14.1. Secondary Research 14.2. Expert Panel Validation

Table 1. Diagnostic Guidelines Table 2. Treatment Guidelines Table 3. Assessment Summary Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis Table 5. Nontuberculous Mycobacterial Infections Acquisition Analysis Table 6. Assessment by Phase of Development Table 7. Assessment by Product Type (Mono / Combination) Table 8. Assessment by Stage and Product Type Table 9. Assessment by Route of Administration Table 10. Assessment by Stage and Route of Administration Table 11. Assessment by Molecule Type Table 12. Assessment by Stage and Molecule Type Table 13. Assessment by MOA Table 14. Assessment by Stage and MOA Table 15. Late Stage Products (Phase-III) Table 16. Mid Stage Products (Phase-II) Table 17. Early Stage Products (Phase-I) Table 18. Pre-clinical and Discovery Stage Products Table 19. Inactive Products Table 20. Dormant Products Table 21. Discontinued Products Figure 1. Disease Overview Figure 2. History Figure 3. Symptoms Figure 4. Causes Figure 5. Pathophysiology Figure 6. Diagnostic Guidelines Figure 7. Treatment Guidelines Figure 8. Nontuberculous Mycobacterial Infections companies collaborations, Licensing, Acquisition –Deal Value Trends Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis Figure 10. Nontuberculous Mycobacterial Infections Acquisition Analysis Figure 11. Assessment by Phase of Development Figure 12. Assessment by Product Type (Mono / Combination) Figure 13. Assessment by Stage and Product Type Figure 14. Assessment by Route of Administration Figure 15. Assessment by Stage and Route of Administration Figure 16. Assessment by Molecule Type Figure 17. Assessment by Stage and Molecule Type Figure 18. Assessment by MOA Figure 19. Assessment by Stage and MOA Figure 20. Late Stage Products (Phase-III) Figure 21. Mid Stage Products (Phase-II) Figure 22. Early Stage Products (Phase-I) Figure 23. Pre-clinical and Discovery Stage Products Figure 24. Inactive Products Figure 25. Dormant Products Figure 26. Discontinued Products Figure 27. Unmet Needs

Savara Pharmaceuticals Vertex Pharmaceuticals Insmed Merck & Co Matinas BioPharma Beyond Air Hsiri Therapeutics Pfizer RedHill Biopharma